Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16294301 | 0.84 | RAB9A (0.36) | RAB9AKMT2ANPC1KDM4EMEN1 | |
| SCHEMBL1416233 | 0.82 | ALOX5 (0.34) | ALDH1A1MAPTSMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL3120587 | 0.82 | GAA (0.41) | SMN1; SMN2KMT2AOPRM1OPRL1HSD17B10 | |
| SCHEMBL7018147 | 0.81 | OPRM1 (0.32) | ALDH1A1MAPTTSPOSMN1; SMN2KMT2A | |
| SCHEMBL1416613 | 0.79 | ROCK2 (0.35) | ALDH1A1SMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL2535686 | 0.79 | TSHR (0.42) | ALDH1A1MAPTRAB9AKMT2ANPC1 | |
| SCHEMBL2537879 | 0.79 | NPC1 (0.33) | ALDH1A1MAPTTSPOSMN1; SMN2RAB9A | |
| SCHEMBL482524 | 0.79 | KMT2A (0.45) | ALDH1A1SMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL7838941 | 0.78 | AOC3 (0.41) | RAB9AKMT2ANPC1GAA | |
| SCHEMBL7839570 | 0.78 | KDM4E (0.38) | ALDH1A1RAB9AKMT2ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0233461-B2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 2002-05-29 | — | — | EP | claimed |
| US-5516775-A | TO INHIBIT PROTEIN KINASE C | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | claimed |
| EP-0233461-B1 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 1996-03-20 | — | — | EP | claimed |
| EP-0588762-A1 | Use of pyrimidine derivatives as inhibitors of proteinkinase C and antitumor drugs | CIBA-GEIGY AG (CH) | 1994-03-23 | — | — | EP | claimed |
| EP-0201201-B1 | AMIDO SUBSTITUTED DIVALENT CHALCOGENIDE FOG INHIBITING AGENTS FOR SILVER HALIDE PHOTOGRAPHY | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1991-01-02 | — | — | EP | claimed |
| US-4788195-A | TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1988-11-29 | — | — | US | claimed |
| EP-0233461-A2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID COMPANY (US) | 1987-08-26 | — | — | EP | claimed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2020-04-02 | — | — | US | disclosed |
| EP-3406596-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-20180265454-A1 | Method for Producing 4-Oxoquinoline Compound | JAPAN TOBACCO INC. (JP) | 2018-09-20 | — | — | US | disclosed |
| US-20150299104-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| US-4876252-A | ADMINISTERING ANTIASTHMATIC OR ANTIALLERGEN | AMERICAN CYANAMID COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| US-4816372-A | Heat development process and color photographic recording material suitable for this process | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1989-03-28 | — | — | US | disclosed |
| US-4788195-A | TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1988-11-29 | — | — | US | disclosed |
| US-4740446-A | CONTAINING CYCLIC UREA COMPOUND AS DIFFUSION PROMOTING AGENT | AGFA GEVAERT AKTIENGESELLSCHAFT (DE) | 1988-04-26 | — | — | US | disclosed |
| EP-0261567-A2 | Heat development process and colour-photographic recording material suitable therefor | Agfa-Gevaert AG (DE) | 1988-03-30 | — | — | EP | disclosed |
| EP-0233461-A2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID COMPANY (US) | 1987-08-26 | — | — | EP | disclosed |
| US-4139537-A | 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds | COOPER LABORATORIES, INC. (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299104-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | IMPDH1, IMPDH2, CDK20 | ALDH1A1 2769/4885MAPT 4278/4885TSPO 3869/4885 |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | ALDH1A1 712/4885MAPT 3144/4885TSPO 4294/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | ALDH1A1 717/4885MAPT 2829/4885TSPO 4206/4885 |
| US-20180265454-A1 | Method for Producing 4-Oxoquinoline Compound | IMPDH1, IMPDH2, CDK20 | ALDH1A1 2769/4885MAPT 4278/4885TSPO 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.